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Objectives The goal of this study was to estimate the population burden of heart failure and the influence of modifiable risk
factors.
Background Heart failure is a common, costly, and fatal disorder, yet few studies have evaluated the population-level influ-
ence of modifiable risk factors.
Methods From 14,709 ARIC (Atherosclerosis Risk in Communities) study participants, we estimated incidence rate differ-
ences (IRD) for the association between 5 modifiable risk factors (cigarette smoking, diabetes, elevated low-
density lipoproteins, hypertension, and obesity) and heart failure. Potential impact fractions were used to mea-
sure expected changes in the heart failure incidence assuming achievement of a 5% proportional decrement in
the prevalence of each risk factor.
Results Over an average of 17.6 years of follow-up, 1 in 3 African American and 1 in 4 Caucasian participants were hos-
pitalized with heart failure, defined as the first hospitalization with International Classification of Diseases, Ninth
Revision discharge codes of 428.x. Of the 5 modifiable risk factors, the largest IRD was observed for diabetes,
which was associated with 1,058 (95% confidence interval [CI]: 787 to 1,329) and 660 (95% CI: 514 to 805)
incident hospitalizations of heart failure/100,000 person-years among African-American and Caucasian partici-
pants, respectively. A 5% proportional reduction in the prevalence of diabetes would result in approximately 53
and 33 fewer incident heart failure hospitalizations per 100,000 person-years in African-American and Cauca-
sian ARIC participants, respectively. When applied to U.S. populations, this reduction may prevent approximately
30,000 incident cases of heart failure annually.
Conclusions Modest decrements in the prevalence of modifiable heart failure risk factors such as diabetes may substantially
decrease the incidence of this major disease. (J Am Coll Cardiol 2012;60:1640–6) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.022Heart failure is a common, costly, disabling, and often fatal
disorder that affects approximately 5.8 million Americans
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accepted July 2, 2012.(1). Despite improvements in medical care and advances in
therapy, hospital discharges for heart failure have increased
155% over the past 2 decades (2), and heart failure has
become the most common cause for hospital admission (3)
and readmission (4). Although the considerable morbidity
and mortality attributed to heart failure can be reduced by
treatment (5,6), approximately half of those with heart
failure die within 5 years of diagnosis (2). Thus, the aging
U.S. population, combined with heart failure treatment
costs that are the most expensive of all Medicare diagnoses
(7), make heart failure a major—and growing—public
health burden.
Numerous studies have evaluated associations between
heart failure and risk factors including previous coronary
heart disease (CHD), elevated blood pressure, hypercholes-
terolemia, overweight/obesity, cigarette smoking, and ar-
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October 23, 2012:1640–6 Population Burden of Heart Failurerhythmias (8,9). Yet, few have explicitly measured the
population burden of heart failure attributable to modifiable
risk factors (10–12). Population burden measures, for ex-
ample, the population impact fraction (13), are of direct
relevance for primary prevention, resource allocation, and
research prioritization, because they estimate the number of
events that may be preventable if the prevalence of a
modifiable risk factor was reduced. Similarly useful for
informing heart failure research agendas and primary pre-
vention efforts are disability-adjusted life-years (DALYs),
which inform on premature mortality and years lived with
disability (YLD) (14,15). Therefore, we evaluated the pop-
ulation burden of heart failure measured by the lifetime risk,
incidence rate differences (IRD), DALYs, and potential
impact fractions (PIF) in 14,709 ARIC (Atherosclerosis
Risk in Communities) study participants.
Materials and Methods
Study population. The ARIC study includes an ongoing
population-based cohort of 15,792 Caucasian and African-
American men and women aged 45 to 64 years at baseline
that was recruited in 1987 to 1989 using probability sam-
pling from 4 U.S. communities: Forsyth County, North
Carolina, the northwest suburbs of Minneapolis, Minne-
sota, Washington County, Maryland, and Jackson, Missis-
sippi (16). Standardized physical examinations and
interviewer-administered questionnaires were conducted at
baseline and at 3 triennial follow-up examinations. Partic-
ipant follow-up through annual telephone interviews and
review of hospitalization records and vital status is ongoing.
Institutional review boards at each participating institution
approved the ARIC study, and all participants provided
informed consent before each examination.
We excluded a total of 1,083 participants (6.8% of the
total ARIC cohort) from the analysis: 755 participants with
prevalent heart failure; 280 participants missing data on
variables used to assess prevalent heart failure; and 48
participants who did not self-report a race of Caucasian or
African American. After these exclusions, the total sample
size was 14,709 participants.
Exposure and covariate definitions. We examined 5 po-
tentially modifiable cardiovascular risk factors, which were
assessed at study baseline and at 3 triennial examinations:
current smoking, diabetes, elevated low-density lipoprotein
concentration (LDL), hypertension, and obesity. Criteria
for inclusion in this study included the availability of
measures at all 4 ARIC visits, previously documented
associations with the incidence of heart failure, and amena-
bility to change. Current smoking status was ascertained by
interviewer-administered questionnaire. Diabetes was de-
fined as fasting plasma glucose 126 mg/dl, nonfasting
glucose 200 mg/dl, self-reported use of diabetes medica-
ions, or self-reported physician diagnosis of diabetes. Ele- cvated LDL was defined as LDL
160 mg/dl or self-reported use
of lipid-lowering medications.
Participants with systolic blood
pressure 140 mm Hg, diastolic
lood pressure 90 mm Hg, or
ho reported the use of medica-
ions for blood pressure control
ere classified as hypertensive.
ody mass index dichotomized
t 30 kg/m2 was used to define
besity. Serum creatinine was
easured and analyzed as previ-
usly described (17). We calcu-
ated estimated glomerular filtra-
ion rate using the CKD-EPI
Chronic Kidney Disease Epide-
iology Collaboration) equation
18). Medication use was ascertained by medication inventory
sing Medi-Span Therapeutic Classification codes.
scertainment of incident heart failure events. Heart
ailure events were ascertained through active surveillance of
ocal hospital discharge lists to identify hospitalizations with
ardiovascular disease diagnoses. Yearly interviews of co-
ort members during which all hospitalizations were
eported were also conducted to identify hospitalizations
hat occurred outside the ARIC catchment areas. Inci-
ent heart failure hospitalizations were defined as the first
ecorded hospitalization with International Classification
f Diseases–Ninth Revision discharge codes of 428.x in
ny position. Validation of heart failure hospitalizations
ndicated that the positive predictive value of 428.x was
3% for acute decompensated heart failure and 97% for
hronic heart failure (19). Heart failure hospitalization
ata were available from study baseline through Decem-
er 31, 2008.
scertainment of incident coronary heart disease and
troke events. To facilitate comparisons with lifetime
isk estimates of heart failure, we also examined incident
HD and stroke events. Incident CHD was defined as a
alidated definite or probable hospitalized myocardial
nfarction (MI), a definite CHD death, or an unrecog-
ized MI defined by ARIC electrocardiogram readings.
he criteria for definite or probable hospitalized MI were
ased on combinations of chest pain symptoms, electro-
ardiogram changes, and cardiac enzyme levels (20). An
ncident stroke occurrence was defined as a first definite
r probable hospitalized stroke occurring in a participant
ree of a history of physician-diagnosed stroke at the
aseline interview. Adjudicated events were available
rom baseline through December 31, 2008.
tatistical analysis. Race-specific lifetime risk estimates
onditional on survival free of each disease to age 45 years
nd accounting for the competing risk of death were
Abbreviations
and Acronyms
CHD  coronary heart
disease
DALYs  disability-adjusted
life-years
IRD  incidence rate
difference
LDL  low-density
lipoprotein
MI  myocardial infarction
PIF  potential impact
fractions
YLD  years lived with
disability
YLL  years of life lostalculated as:
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* 
jAmin
A
hAUˆA1
where A represents age, j indexes ordered failure times
mong N participants, h is the hazard or conditional
robability estimate of developing the disease at time tj
given survival beyond time tj-1, and Û is the estimated
urvival probability (21). The timescale of interest was age;
articipants contributed to the risk set beginning at their age
f entry into the cohort. Accounting for competing risks was
ecessary because traditional survival analytic techniques
e.g., the Kaplan-Meier method [22]) assume that heart
ailure is still possible beyond the time of censoring (21);
ince heart failure, stroke, and CHD cannot occur after
eath, death was defined as a competing risk. The variance
f the cumulative incidence was estimated using a Taylor
eries linear expansion (23). Confidence intervals for inci-
ence rates were estimated using a method described by
aenszel (24). Age-adjusted rates were directly standard-
zed to the entire population. Poisson regression was used to
stimate race-specific IRDs for the 5 modifiable risk factors
djusting for age (in 10-year categories) and sex. Event time
as defined as the time until the first heart failure
ospitalization.
Using the PIF, we estimated the expected proportional
hange in the average heart failure incidence, assuming a
eduction in the prevalence of a categorical outcome with n
iscrete levels:

i1
n
Pi RRi
i1
n
P'i RRi

i1
n
P'i RRi
where RR(i) represents the relative risk at exposure level i,
P(i) is the population prevalence, and P’(x) is the counter-
factual population prevalence (13). Proportional reductions
in the prevalence of a given risk factor imply a shift below
the risk factor threshold of the corresponding proportion of
the population (i.e., into the unexposed population group).
Race-, sex-, and age-specific (10-year categories) RRis were
recombined by race using a case-load–weighted sum
method (10).
DALYs were used to quantify disability, because direct
measures of disability and functional limitations were un-
available. DALYs are a commonly used health metric that
was introduced in the mid-1990s by the World Health
Organization Global Burden of Disease project so that
nonfatal outcomes spanning cancers, cardiovascular dis-
eases, and infectious diseases could be considered on a
common scale for the evaluation of health resource use and
research prioritization (15,25). Specifically, DALYs com-
bine data on mortality (years of life lost [YLL]) and nonfatal
health outcomes (YLD) into a single measure that estimates
the difference between current and ideal health states (26–28).
DALYs were calculated as the sum of YLL and YLD:DALYs  YLLs  YLDs
where
YLLs  number of deaths  life expectancy at age of death
and
YLDsnumber of years with a disabilitydisability weight
Disability following heart failure hospitalizations was not
directly measured. Instead, a disability weight was used to
indicate the severity of disease on a scale from 0 to 1. A
disability weight of 0 indicates perfect health (i.e., no disability)
and a disability weight of 1 indicates death. The disability
weight assigned to heart failure by the Global Burden of
Disease panel of reviewers was 0.201 (29).
The burden of disease due to mortality (i.e., YLLs) was
calculated as the race-, sex-, and age-specific (5-year age
groups) 1-year mortality rate multiplied by the age-specific
life expectancy based on year 2004 U.S. life tables. For YLD
estimation, an incidence-based approach was adopted that
measured years with disability as incidence  duration,
defined as the incidence of heart failure multiplied by the
mean duration of disability, in race, sex, and 5-year age
intervals (14). The mean duration of disability was esti-
mated by the median survival time following the first heart
failure hospitalization. For the calculation of DALYs attrib-
utable to heart failure risk factors, DALYs were multiplied
by the population attributable fraction (30) for each risk
factor and the specified proportional reduction in the
exposure (5% assumed), assuming a constant disease pro-
gression for each risk factor. This resulting metric is
interpreted as the absolute reduction in DALYs (measured
in years) associated with a population-level reduction in a
given exposure. All statistical analyses were performed using
SAS version 9.1 (SAS Institute, Cary, North Carolina).
Results
ARIC participants contributed an average of 17.6 years of
person-time through 2008, during which 2,102 heart failure
cases were identified (Table 1). The 1-year age-adjusted
incidence rate of heart failure was higher in African Amer-
icans (1,126/100,000 person-years) compared with Cauca-
sians (676/100,000 person-years) (Table 2), as was the
prevalence of hypertension, diabetes, and chronic kidney
disease. Median survival among Caucasian participants with
heart failure following the index hospitalization was 8.6
years, approximately 4 years longer than the median survival
among African-American participants (4.9 years). An esti-
mated 196 African Americans (27.4%) and 349 Caucasians
(25.2%) died within 1 year of their incident heart failure
hospitalization.
The lifetime risk of heart failure adjusted for competing
risk of death for adults over 45 years old was 32.8% (95%
confidence interval [CI]: 27.4 to 36.1) or 1 in 3 for African
r1643JACC Vol. 60, No. 17, 2012 Avery et al.
October 23, 2012:1640–6 Population Burden of Heart FailureAmericans and 25.9% (95% CI: 22.7 to 28.0) or 1 in 4 for
Caucasian participants (Fig. 1). For both Caucasian and
African-American participants, the lifetime risk of hospi-
talized heart failure was higher than the lifetime risk of
incident CHD and incident stroke.
Of the 5 modifiable risk factors we examined (current
smoking, diabetes, elevated LDL, hypertension, and obe-
sity), diabetes was associated with the largest IRD (Fig. 2).
Specifically, diabetes accounted for 1,058 (95% CI: 787 to
1,329) and 660 (95% CI: 514 to 805) incident cases of heart
failure per 100,000 person-years among African-American
and Caucasian participants, respectively. IRD estimates for
current smoking, elevated LDL, hypertension, and obesity
were generally consistent across African-American and
Caucasian populations, although IRD estimates for elevated
LDL and hypertension were slightly elevated among
African-American ARIC participants. As a sensitivity anal-
ysis, we examined how robust IRD estimates were to
adjustment for all risk factors together and beta blocker,
ACE inhibitor, and diuretic use. Inferences were robust to
adjustment for both the combined risk factors and medica-
tion use (results not shown).
Heart failure was also associated with disability and early
mortality. In the ARIC cohort, heart failure was associated
with 9,527 YLLs. Approximately 12,473 years of life were
lived following the incident heart failure hospitalization;
multiplying this estimate by the heart failure disability
weight of 0.201 yielded 2,507 YLD. Together, the YLD
and YLL estimates indicated that, on average, ARIC
participants with heart failure experienced 5.7 DALYs, the
majority representing early mortality.
Finally, we evaluated how population-level reductions in
the prevalence of modifiable heart failure risk factors may
Baseline Characteristics of ARIC StudyP rticipants (N  14,709) by Race, 1987–1989Table 1 B seline Characteristics of ARIC StudyParticipants (N  14,709) by Race, 1987–1989
Characteristics
African Americans
(n  3,902)
Caucasians
(n  10,807)
Mean age, yrs 53 5.8 54 5.7
Female 2,374 (60.8) 5,140 (47.6)
Mean BMI, kg/m2 29.4 6.1 26.9 4.8
Prevalent CHD 117 (3.0) 483 (4.5)
Current smoker 1,169 (30.0) 2,645 (24.5)
Diabetes 706 (18.6) 918 (8.5)
High school education 2,314 (59.4) 8,971 (83.1)
Hypertension 2,080 (53.3) 2,741 (25.4)
eGFR, ml/min/1.73 m2 104.0 19.6 95.7 14.9
eGFR 60 ml/min/1.73 m2 84 (2.2) 159 (1.5)
Mean LDL, mg/dl 137.4 42.7 137.7 37.9
ACE inhibitor use 305 (2.8) 161 (4.3)
Diuretics use 846 (22.1) 1,226 (11.4)
Beta blocker use 367 (9.4) 1,083 (10.1)
Values are mean SD or n (%).
ACE  angiotensin-converting enzyme; ARIC  Atherosclerosis Risk in Communities study;
BMI  body mass index; CHD  coronary heart disease; eGFR  estimated glomerular filtration
ate; LDL  low-density lipoprotein concentration.influence estimates of the incidence of disease, disability,and early mortality. As shown in Table 3, modest decre-
ments in the population prevalence of modifiable risk factors
would decrease the heart failure incidence. For example, a
5% proportional reduction in the prevalence of diabetes in
ARIC African-American participants (i.e., reducing the
diabetes prevalence from 31.0% to 29.5%) would result in
approximately 53 fewer heart failure cases per 100,000
person-years (Table 3). A 5% proportional reduction in the
prevalence of diabetes in ARIC would also decrease the
estimated number of heart failure DALYs by 183 years
overall, largely reflecting a reduction in the number of
YLLs.
Discussion
In this biracial cohort of middle-aged men and women, we
estimated a lifetime risk of heart failure of 1 in 3 for African
Americans and 1 in 4 for Caucasians. Heart failure was also
associated with early mortality and disability. However, we
estimated that a 5% reduction in modifiable heart failure
risk factors would markedly decrease the incidence of
disease, as well as heart failure–related early mortality and
disability, in this population.
Few studies have reported estimates of the population
burden of heart failure (10–12). Lifetime risk estimates, for
example, are useful because they may be more easily under-
stood by clinicians and patients than relative effect measures
and can be compared across diseases to understand compet-
ing causes of morbidity and mortality (31). Several studies
have reported lifetime risk estimates of heart failure in
populations of European descent (11,32,33), which were
comparable in magnitude to lifetime risks of heart failure we
estimated among Caucasians. However, to our knowledge,
we are the first to present such estimates in an African-
American population and show that the lifetime risk of
heart failure is 1 in 3, which is higher than that of stroke or
CHD in the same population.
Evaluating disability is especially important for condi-
tions such as heart failure, which occurs primarily in the
elderly and is characterized by a heavy comorbidity burden.
Yet, few studies have quantified the heart failure disability
burden and compared it with other major diseases. One
exception is a Dutch study that used data from the mid-
Race-Specific Incidence Rates of HF per 100,000Person-Years, the ARIC Cohort Study, 1987–2008Table 2 Rac -Spe ific Incidence Rates of HF per 100,000Person-Years, the ARIC Cohort Study, 1987–2008
Age Group
African Americans Caucasians
Events, n
Incidence
Rate/100,000 Events, n
Incidence
Rate/100,000
45–54 yrs 34 260 40 132
55–64 yrs 238 818 308 379
65–74 yrs 334 1,581 662 946
75 yrs 110 2,410 376 2,039
Total 716 1,126* 1,386 676**HF incidence rate is age adjusted.
ARIC  Atherosclerosis Risk in Communities; HF  heart failure.
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disability were comparable in magnitude to dementia and
colon and rectal cancer (34). It is difficult to extrapolate
these results to present-day populations, given demographic
shifts and differences in risk factor burdens among coun-
tries. Future studies of heart failure should therefore lever-
age validated outcome measurements from contemporary
studies.
Analyses examining 5 modifiable heart failure risk factors
suggested that in the ARIC study, diabetes was associated
with the greatest population burden of heart failure when
compared with current smoking, elevated LDL, hyperten-
sion, and obesity. Diabetes is a known risk factor, being
associated with stage A heart failure (35), although hyper-
tension and CHD are traditionally viewed as the strongest
heart failure risk factors. Although IRD estimates presented
herein may seem of small magnitude, extrapolations to a
Figure 1 Lifetime Risk Estimates of Heart Failure, CHD, and St
Race-specific lifetime risk of incident hospitalized heart failure (A), incident coronary h
Lifetime risks are estimated conditional on survival to age 45 years and adjusted for a
Figure 2 Incidence Rate Differences for 5 Modifiable
Heart Failure Risk Factors
Race-specific estimated heart failure incidence rate differences for current smok-
ing, diabetes, elevated low-density lipoprotein (LDL), hypertension, and obesity, the
ARIC study, 1987 to 2008. Incidence rate difference estimates are adjusted for
age and sex and are presented per 100,000 person-years.U.S. African-American and Caucasian population age 45
years or greater suggest that approximately 30,000 annual
incident cases of heart failure may be prevented by modest
decrements in this modifiable risk factor. Of note, this
estimate does not consider the effect of reducing incident
HF cases on subsequent rehospitalizations for these pre-
vented incident events.
Although population-attributable risk estimates are more
commonly reported in studies examining the population
burden of heart failure (12,36), we chose to present PIFs, as
these estimates do not presume complete elimination of a
given risk factor. Here, we considered a 5% proportional
reduction in 5 modifiable risk factors that have been
consistently associated with heart failure. A 5% proportional
reduction in the prevalence of diabetes is less ambitious than
Healthy People 2010’s goals, which aim to reduce the
age-adjusted prevalence of clinically diagnosed diabetes
from a baseline of 40 cases/1,000 people (in 1997) to the
Healthy People 2010 target of 25 cases/1,000 people, a
37.5% reduction. However, age-adjusted rates for diabetes,
obesity, and cigarette smoking have increased over the past
decade (37), underscoring the need for more aggressive
evidence-based prevention efforts. It also highlights the
importance of focusing on interventions that are practical, as
the estimates presented herein are meaningless unless inter-
ventions are available and feasible to implement.
Study strengths and limitations. The strengths of this
study include the standardized and repeated assessment of
heart failure risk factors in a biracial, population-based
cohort and an extended follow-up of participants with high
retention (90%). One limitation is that we did not include
outpatient events, although Roger et al. (2004) (2) sug-
gested that the majority of heart failure cases identified in
outpatient settings were hospitalized within 1.7 years. It is
also unclear whether our results are generalizable to the
present-day United States, as only 4 communities were
sease (CHD) (B), and incident stroke (C), the ARIC study, 1987 to 2008.
eting risk of death.roke
eart di
comprepresented in the ARIC study, and we included heart
ost; oth
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However, risk factor profiles estimated in ARIC partici-
pants are similar to those reported in other population-
based U.S. studies (1). We also report PIF estimates that
consider each potentially modifiable risk factor separately,
although these 5 risk factors often cluster together, and
interventions to reduce the prevalence of one would likely
affect the prevalence of the others. Likewise, we did not
evaluate the influence of population shifts in physical
activity and diet on the incidence of heart failure, although
such interventions would likely be necessary to achieve
lasting population-level changes in cardiometabolic risk
factors. Future research examining the interrelationship
between the modifiable heart failure risk factors examined
herein and the utility of shifting physical activity and diet
patterns is clearly needed.
Finally, we focused on clinically defined cut-points for
potentially modifiable risk factors, including diabetes, ele-
vated LDL, adiposity, and elevated blood pressure, as
opposed to interval scale exposure values. One advantage of
predefined cut-points was that we were able to avoid strong
assumptions about the relation between the exposures and
risk of disease. The clinical cut-points are also well under-
stood and provide estimates of the potential impact clini-
cians could achieve by adhering to current practice guide-
lines. However, small reductions in heart failure risk factors,
such as a 1 or 2 mg/dl shift in the population distribution of
fasting plasma glucose, may be more easily achievable on a
population level and should be examined further (38,39).
Examining the burden of modifiable risk factors in popula-
tions at high risk for heart failure, including those with atrial
fibrillation, coronary heart disease, or chronic kidney dis-
ease, is also warranted.
Randomized clinical trials have supported the utility of
pharmacological interventions to improve survival in popu-
lations with heart failure (5,6), yet prognosis remains bleak.
Given the aging of the population, improved post-MI
survival, and the increasing prevalence of modifiable heart
failure risk factors, primordial prevention of heart failure
likely provides the greatest opportunity for reducing the
incidence of this major disease. Although additional studies
Race-Specific Estimates of the Preventable Number of HF Cases, YTable 3 Race-Specific Estimates of the Preventable Number of
Exposure
African Americans
Period Prevalence,
1987–1998*
Preventable Number
of HF cases†
DALYs
Number of YLL‡ Num
Current smoking 32.4 15 28
Diabetes 31.0 53 65
Elevated LDL 65.4 23 60
Hypertension 71.1 28 68
Obesity 50.2 16 39
Estimates are based on what would result from a 5% proportional reduction in the prevalence of 5 ca
‡per year for all participants with heart failure.
DALYs  disability-adjusted life-years; YLD  years living with disability; YLL  years of life lare needed to verify the estimated magnitude of effectbetween the modifiable risk factors we examined and heart
failure, our results suggest that modest improvements in the
population prevalence of modifiable heart failure risk factors
may decrease both the incidence of disease and the number
of years lost or lived with disability.
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